The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study

NCT01217476 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Foot Ulcer of Neuropathic Origin

Interventions

DRUG: Trafermin 0.01% spray

Sponsor

Olympus Biotech Corporation